CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

The new Express License service removes barriers to accessing this transformative gene editing technology for ... simple and affordable access to the CRISPR/Cas9 patent portfolio through a non ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

received the National Medal of Technology and Innovation in recognition of his work developing the revolutionary gene-editing tool CRISPR-Cas9. According to the citation from the US Patent and ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

The work has been reported in Nature Communications. SPLICER is a modification of the well known gene-editing technique known as CRISPR, in which a guide RNA takes a DNA-cutting enzyme called Cas9 to ...

Lutz: For sure, automation is facilitating any gene editing techniques for clone generation. According to a recent [internal] survey about CRISPR-Cas9, single-cell cloning poses the biggest ...

Not long after the development of CRISPR-Cas9 gene editing in 2013, Vallabh and Minikel began thinking about whether CRISPR could be used to disrupt the gene encoding the prion protein.

CRISPR-Cas9 genome ... genome editing. Scientists argue that the technology involves considerable risk and uncertain benefits. Although compact Un1Cas12f1 has improved, low gene editing activity ...